Date: 2012-08-23
Type of information: Initiation of the trial
phase: 3
Announcement: initiation of the trial
Company: Bayer Healthcare (Germany)
Product: drug-device combination Ciprofloxacin Dry Powder for Inhalation
Action mechanism:
Disease: non-cystic fibrosis bronchiectasis (NCFB)
Therapeutic area: Respiratory diseases
Country: multinational study
Trial
details: The global RESPIRE programme will comprise two multinational, randomized, placebo-controlled, double-blind, multi-centre studies that will further investigate the clinical efficacy and safety of chronic, intermittent ciprofloxacin DPI therapy in non-cystic fibrosis bronchiectasis.
Latest
news: Bayer HealthCare has announced the start of its Phase III programme RESPIRE evaluating their innovative drug-device combination Ciprofloxacin Dry Powder for Inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis (NCFB). The programme will run globally and investigates the clinical efficacy and safety of chronic, intermittent ciprofloxacin DPI therapy in NCFB.
